Newsroom | 5052 results

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced today that it has entered into a definitive securities purchase agreement for the purchase and sale of an aggregate of 2,522,727 shares of its common stock in a private placement at a price of $4.40 per share. The offering is expecte...

CAMBRIDGE, England & DETROIT--(BUSINESS WIRE)--Cycle Group Holdings Limited (“Cycle” or “Parent”) today announces that AT2B, Inc., a Delaware corporation (“Purchaser”) and indirect wholly owned subsidiary of Cycle, has extended the expiration date of its tender offer to purchase all of the outstanding shares of common stock, par value $0.0001 per share of Applied Therapeutics, Inc., a Delaware corporation (“Applied”) for (i) $0.088 per share, net to the seller in cash, without interest, plus (i...

FRANKFURT, Germany--(BUSINESS WIRE)--Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerati...

TURIN, Italie--(BUSINESS WIRE)--Reply [EXM, STAR : REY] a annoncé aujourd’hui le début d’une collaboration avec le département de physiopathologie et de transplantation de l’Université de Milan, en collaboration avec le « Centro Dino Ferrari » de l’Université de Milan - Ospedale Policlinico, pour une nouvelle initiative de recherche et d’expérimentation dans le domaine de l’informatique biologique. Le projet vise à explorer des approches innovantes en matière d’apprentissage et de traitement de...

TURIN, Italië--(BUSINESS WIRE)--Reply [EXM, STAR: REY] heeft vandaag aangekondigd dat het een samenwerking aangaat met de afdeling Pathofysiologie en Transplantatie van de Universiteit van Milaan, en het "Centro Dino Ferrari" van de Universiteit van Milaan - Ospedale Policlinico. Het gaat om een nieuw experimenteel onderzoeksinitiatief op het gebied van biologische informatica. Het project heeft tot doel innovatieve benaderingen van leren en informatieverwerking te bestuderen door middel van de...

TURIN, Italia--(BUSINESS WIRE)--Reply [EXM, STAR: REY] ha anunciado hoy el inicio de una colaboración con el Departamento de Fisiopatología y Trasplantes de la Universidad de Milán, junto con el «Centro Dino Ferrari» de la Universidad de Milán - Ospedale Policlinico, para una nueva iniciativa de investigación y experimentación en el campo de la informática biológica. El proyecto tiene como objetivo explorar enfoques innovadores para el aprendizaje y el procesamiento de la información mediante l...

CAMBRIDGE, England & DETROIT--(BUSINESS WIRE)--Cycle Group Holdings Limited (“Cycle” or “Parent”) today announces that AT2B, Inc., a Delaware corporation (“Purchaser”) and indirect wholly owned subsidiary of Cycle, has extended the expiration date of its tender offer to purchase all of the outstanding shares of common stock, par value $0.0001 per share of Applied Therapeutics, Inc., a Delaware corporation (“Applied”) for (i) $0.088 per share, net to the seller in cash, without interest, plus (i...

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) today announced the appointment of Roger Adsett to its Board of Directors effective immediately. “We are thrilled to welcome Roger to our Board of Directors,” said Rob Barrow, Chief Executive Officer of Definium Therapeutics. “Roger is a respected and proven leader with deep experience building high-performing commercial organizations and guiding transformational therapies from launch to meaningful ma...

LUGANO, Zwitserland--(BUSINESS WIRE)--SFI Health™ EMEA, de regionale entiteit van SFI Health™, wereldwijd toonaangevend op het gebied van natuurlijke gezondheidszorg, kondigt vandaag met trots de lancering aan van Equazen® Forte in Polen. Deze nieuwe geconcentreerde omega 3-productformule wordt toegevoegd aan het Equazen®-assortiment en is ontworpen om de normale cognitieve prestaties van jongvolwassenen en volwassenen te ondersteunen. Deze bekendmaking is officieel geldend in de originele bron...

LUGANO, Suiza--(BUSINESS WIRE)--SFI Health™ EMEA, entidad regional de SFI Health™, líder mundial en salud natural, acaba de anunciar el lanzamiento de Equazen® Forte en Polonia, una nueva fórmula concentrada de omega 3 que se incorpora a la gama Equazen® y que está diseñada para apoyar el rendimiento cognitivo normal de jóvenes y adultos. El comunicado en el idioma original es la versión oficial y autorizada del mismo. Esta traducción es solamente un medio de ayuda y deberá ser comparada con el...